Wow, so excited about this work that reads like a trilogy. First, we re-engineered a fluorescent FRET biosensor for ERK into an improved version EKAREN5 (available at Addgene). Second, we established quantitative real-time ERK-FRET measurements in all tumor cells of drug-challenged organoids. As last, we reveal that upstream EGFR activity matters in tumors, even in the presence of mutant KRAS or BRAF, being a rigorous amplifier of intrinsically limited oncogene-driven signaling.
Categories: News
